FISH4PETS LIMITED

Here is a comprehensive financial health assessment for FISH4PETS LIMITED based on the latest filed accounts up to 31 December 2025.

1. Financial Health Score: C+ (Recovering)

Explanation: The patient has recently emerged from a critical care situation. In 2024, the company exhibited symptoms of severe financial distress, culminating in negative net assets (technical insolvency on paper). However, a major "surgical intervention" in late 2025—a debt-to-equity swap—has successfully stabilized the patient's balance sheet. While the core business metabolism (UK pet food sales) is healthy and growing, the overall grade is held back by a chronic "infection" in an overseas joint venture, which continues to cause financial blood loss and has resulted in a qualified audit opinion.

2. Key Vital Signs

• Pulse (Revenue & Gross Profit): Steady and Strengthening. The core heartbeat of the business is robust. Revenue grew from £12.37m in 2024 to £13.04m in 2025, and gross profit increased from £6.05m to £6.23m. This indicates strong demand for the company's pet food products.
• Blood Pressure (Liabilities vs. Assets): Stabilized following treatment. In 2024, liabilities (£5.55m) exceeded total assets, creating dangerous pressure. In 2025, total liabilities were nearly halved to £2.43m against total assets of £4.44m, restoring a healthy positive net asset position of £1.75m.
• Blood Count (Cash Reserves): Adequate but slightly lowered. Cash on hand dropped from £1.01m to £648k. While the company reports generating positive cash flows during the year, the ending cash balance is a bit lower, likely a side effect of the financial restructuring and debt management activities.
• Organ Function (Shareholders' Equity): Massive Transfusion. Shareholders' funds underwent a dramatic transformation, jumping from a deeply negative £-19.29m in 2024 to a robust £22.28m in 2025. This was achieved by converting £4.42m of accumulated debt into equity, effectively curing the negative equity condition.

3. Diagnosis

Symptoms Analysis: The financial data reveals a tale of two patients living in the same body. The first is a healthy, growing UK-based pet food manufacturer. The second is a struggling overseas venture causing systemic issues.

Overall Financial Condition: * The Core Business (Healthy): The directors' report confirms a year of positive EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), reduced administrative costs, and growing sales. This means the day-to-day operations of making and selling pet food are profitable and self-sustaining. * The Balance Sheet (Stabilized): The debt-to-equity swap in December 2025 was a life-saving procedure. By converting debt to equity, the company relieved the crushing pressure of liabilities that had pushed it into negative net assets in 2024. The balance sheet is now fit for purpose. * The Overseas Joint Venture (Chronic Condition): The company has an investment in a Chinese associate (Fish4Dogs Pet Food Foshan). This investment has suffered significant impairments (£1.08m in 2025, on top of £950k in 2024). This is the primary cause of the reported pre-tax loss of £1.59m. Furthermore, the auditors issued a "Qualified Opinion" because they were denied access to the local Chinese auditors' work. This is akin to a doctor being unable to scan a tumor—there is a significant blind spot in the diagnosis of this asset's true value.

4. Recommendations

To improve financial wellness and move the health score into the A/B range, the following treatments are prescribed:

1. Treat the Foreign Complication (Chinese JV): The recurring impairments and the qualified audit opinion are serious symptoms. The directors must either gain full transparency and control over the Fish4Dogs Pet Food (Foshan) Co., Ltd operations to satisfy auditors, or amputate the exposure by divesting from the joint venture to stop the ongoing financial blood loss.
2. Rebuild Cash Reserves: While cash flow was positive, the ending cash balance decreased. With the balance sheet now cleaned up, management should focus on converting future sales into cash to rebuild a stronger liquidity buffer for future economic shocks.
3. Leverage the Clean Bill of Health: With liabilities significantly reduced and equity restored, the company is now in a much stronger position to negotiate favorable terms with suppliers or secure strategic funding for growth if needed. Maintain the current discipline of keeping distribution and administrative costs lean.